A promising approach for the treatment of type 1 diabetes relies upon the implantation, such as in the extra‐peritoneal space, of a macroencapsulation device[2, 3] embedding beta cells in order to produce and deliver insulin in a controlled manner.[4] This macroencapsulation device, the so‐called bioartificial pancreas, allows to isolate the cells from the recipient's immune system. This evidence concerns the gene INS and type 1 diabetes mellitus.